The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 19, 2024

Filed:

Sep. 07, 2018
Applicant:

Nanjing Anji Biological Technology Co., Ltd, Nanjing, CN;

Inventors:

Hanmei Xu, Nanjing, CN;

Erhao Zhang, Nanjing, CN;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 5/0783 (2010.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/18 (2006.01); C07K 16/44 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0636 (2013.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 16/18 (2013.01); C07K 16/44 (2013.01); C07K 2317/24 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/033 (2013.01); C07K 2319/30 (2013.01);
Abstract

The present invention discloses a novel switchable dual chimeric antigen receptor-T (sdCAR-T) cell and a construction method and use thereof, which fall within the field of cellular immunotherapy for tumors. The dual chimeric antigen receptor consists of a first chimeric antigen receptor for MSLN and a second chimeric antigen receptor for FITC. A dual-targeted functional T cells regulated by specific exogenous bifunctional molecules is constructed, and the exogenous molecules are used to preliminarily discuss the in vivo and in vitro activity of the dual chimeric antigen receptor-T cell. By means of in vitro and in vivo tests, it is confirmed that the activation mode of the constructed CAR-T cell is controlled by the combination of endogenous tumor antigens and exogenous bifunctional molecules, and this combined regulation mode can significantly improve the safe application of CAR-T cell immunotherapy.


Find Patent Forward Citations

Quick Actions:

Xu, Hanmei. (2024). Dual chimeric antigen receptor-t cell which can be regulated, construction method therefor and use thereof (U.S. Patent No. 11932872). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/11932872

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…